Related Experiment Videos
Pneumococcal vaccination for older adults: the first 20 years
1Pasteur-Mérieux MSD, Lyon, France. dfedson@fr.pmmsd.com
Drugs & Aging
|February 26, 2000
Summary
Pneumococcal vaccines are highly effective at preventing invasive pneumococcal disease, though their use has been limited. Increased understanding and new vaccine types promise wider use for adults and children globally.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Pneumococcal vaccine licensure has not led to widespread use over 20 years.
- Efficacy demonstrated in specific groups (miners), but pneumonia prevention trials in older adults were inconclusive.
- Observational studies show effectiveness against invasive pneumococcal disease, but acceptance has been gradual.
Purpose of the Study:
- To review the historical use and effectiveness of pneumococcal vaccines.
- To highlight the reasons for limited vaccine uptake.
- To project the future importance of pneumococcal vaccines.
Main Methods:
- Review of historical vaccine usage data.
- Analysis of clinical trial and retrospective study findings.
- Consideration of factors influencing vaccine acceptance and future development.
Main Results:
- Vaccine effectiveness in preventing invasive pneumococcal disease is well-established by retrospective studies.
- Limited uptake due to inconclusive pneumonia prevention trials and skepticism towards observational data.
- Growing recognition driven by better understanding and concerns over antimicrobial resistance.
Conclusions:
- Pneumococcal vaccines are crucial for preventing invasive disease.
- Future vaccine development (conjugate, protein) will increase global importance.
- Wider vaccination is anticipated for both children and adults worldwide.